PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
1.30M / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.00%
FCF growth of 0.00% while XRF.AX is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
-82.85%
Negative 10Y revenue/share CAGR while XRF.AX stands at 103.21%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-77.92%
Negative 5Y CAGR while XRF.AX stands at 69.18%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-51.81%
Negative 3Y CAGR while XRF.AX stands at 58.09%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
134.55%
10Y OCF/share CAGR under 50% of XRF.AX's 4597.97%. Michael Burry would worry about a persistent underperformance in cash creation.
-55.52%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
333.64%
3Y OCF/share CAGR above 1.5x XRF.AX's 16.50%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
No Data
No Data available this quarter, please select a different quarter.
73.19%
5Y net income/share CAGR at 75-90% of XRF.AX's 87.86%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
-390.88%
Negative 3Y CAGR while XRF.AX is 57.31%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.04%
R&D growth of 16.04% while XRF.AX is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
No Data
No Data available this quarter, please select a different quarter.